Patents by Inventor Susan M. Potter
Susan M. Potter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10167346Abstract: Compositions for improving the health of a subject comprise alpha-(1,2)-branched alpha-(1,6) oligodextrans, preferably with an average molecular weight between about 10 kDa and 70 kDa, between about 10% and 50% alpha-(1,2)-osidic side chains, and having at least partial indigestibility in the subject. Methods for improving the health of a subject comprise administering the composition to a subject in an amount effective to improve gut health, or to prevent or treat a gastrointestinal disorder, a cholesterol-related disorder, diabetes, or obesity. Methods for making oligodextrans having controlled size and controlled degree of branching comprise providing alpha-(1,6) oligodextrans having an average molecular weight between 0.5 and 100 kDa and introducing at least 10% alpha-(1,2)-osidic side chains onto the alpha-(1,6) oligodextrans.Type: GrantFiled: October 21, 2016Date of Patent: January 1, 2019Assignee: Tate & Lyle Ingredients France SASInventors: Thierry Naeye, Alexandra Einerhand, Michel Lopez, Susan M. Potter, Magali Remaud-Siméon, Pierre Frédéric Emmanuel Monsan
-
Publication number: 20170101484Abstract: Compositions for improving the health of a subject comprise alpha-(1,2)-branched alpha-(1,6) oligodextrans, preferably with an average molecular weight between about 10 kDa and 70 kDa, between about 10% and 50% alpha-(1,2)-osidic side chains, and having at least partial indigestibility in the subject. Methods for improving the health of a subject comprise administering the composition to a subject in an amount effective to improve gut health, or to prevent or treat a gastrointestinal disorder, a cholesterol-related disorder, diabetes, or obesity. Methods for making oligodextrans having controlled size and controlled degree of branching comprise providing alpha-(1,6) oligodextrans having an average molecular weight between 0.5 and 100 kDa and introducing at least 10% alpha-(1,2)-osidic side chains onto the alpha-(1,6) oligodextrans.Type: ApplicationFiled: October 21, 2016Publication date: April 13, 2017Applicant: TATE & LYLE INGREDIENTS FRANCE SASInventors: THIERRY NAEYE, ALEXANDRA EINERHAND, MICHEL LOPEZ, SUSAN M. POTTER, MAGALI REMAUD-SIMÉON, PIERRE FRÉDÉRIC EMMANUEL MONSAN
-
Patent number: 9512239Abstract: Compositions for improving the health of a subject comprise alpha-(1,2)-branched alpha-(1,6) oligodextrans, preferably with an average molecular weight between about 10 kDa and 70 kDa, between about 10% and 50% alpha-(1,2)-osidic side chains, and having at least partial indigestibility in the subject. Methods for improving the health of a subject comprise administering the composition to a subject in an amount effective to improve gut health, or to prevent or treat a gastrointestinal disorder, a cholesterol-related disorder, diabetes, or obesity. Methods for making oligodextrans having controlled size and controlled degree of branching comprise providing alpha-(1,6) oligodextrans having an average molecular weight between 0.5 and 100 kDa and introducing at least 10% alpha-(1,2)-osidic side chains onto the alpha-(1,6) oligodextrans.Type: GrantFiled: July 11, 2014Date of Patent: December 6, 2016Assignee: TATE & LYLE INGREDIENTS FRANCE SASInventors: Thierry Naeye, Alexandra Einerhand, Michel Lopez, Susan M. Potter, Magali Remaud-Siméon, Pierre Frédéric Emmanuel Monsan
-
Publication number: 20150004140Abstract: Compositions for improving the health of a subject comprise alpha-(1,2)-branched alpha-(1,6) oligodextrans, preferably with an average molecular weight between about 10 kDa and 70 kDa, between about 10% and 50% alpha-(1,2)-osidic side chains, and having at least partial indigestibility in the subject. Methods for improving the health of a subject comprise administering the composition to a subject in an amount effective to improve gut health, or to prevent or treat a gastrointestinal disorder, a cholesterol-related disorder, diabetes, or obesity. Methods for making oligodextrans having controlled size and controlled degree of branching comprise providing alpha-(1,6) oligodextrans having an average molecular weight between 0.5 and 100 kDa and introducing at least 10% alpha-(1,2)-osidic side chains onto the alpha-(1,6) oligodextrans.Type: ApplicationFiled: July 11, 2014Publication date: January 1, 2015Inventors: Thierry NAEYE, Alexandra Eilnerhand, Michel Lopez, Susan M. Potter, Magali Remaud-Siméon, Pierre Frédéric Emmanuel Monsan
-
Patent number: 8816067Abstract: Compositions for improving the health of a subject comprise alpha-(1,2)-branched alpha-(1,6) oligodextrans, preferably with an average molecular weight between about 10 kDa and 70 kDa, between about 10% and 50% alpha-(1,2)-osidic side chains, and having at least partial indigestibility in the subject. Methods for improving the health of a subject comprise administering the composition to a subject in an amount effective to improve gut health, or to prevent or treat a gastrointestinal disorder, a cholesterol-related disorder, diabetes, or obesity. Methods for making oligodextrans having controlled size and controlled degree of branching comprise providing alpha-(1,6) oligodextrans having an average molecular weight between 0.5 and 100 kDa and introducing at least 10% alpha-(1,2)-osidic side chains onto the alpha-(1,6) oligodextrans.Type: GrantFiled: May 7, 2010Date of Patent: August 26, 2014Assignee: Tate & Lyle Ingredients France SASInventors: Thierry Naeye, Alexandra Einerhand, Michel Lopez, Susan M. Potter, Magali Remaud-Siméon, Pierre Frédéric Emmanuel Monsan
-
Publication number: 20100284972Abstract: Compositions for improving the health of a subject comprise alpha-(1,2)-branched alpha-(1,6) oligodextrans, preferably with an average molecular weight between about 10 kDa and 70 kDa, between about 10% and 50% alpha-(1,2)-osidic side chains, and having at least partial indigestibility in the subject. Methods for improving the health of a subject comprise administering the composition to a subject in an amount effective to improve gut health, or to prevent or treat a gastrointestinal disorder, a cholesterol-related disorder, diabetes, or obesity. Methods for making oligodextrans having controlled size and controlled degree of branching comprise providing alpha-(1,6) oligodextrans having an average molecular weight between 0.5 and 100 kDa and introducing at least 10% alpha-(1,2)-osidic side chains onto the alpha-(1,6) oligodextrans.Type: ApplicationFiled: May 7, 2010Publication date: November 11, 2010Applicant: Tate & Lyle Ingredients France SASInventors: Thierry Naeye, Alexandra Einerhand, Michel Lopez, Susan M. Potter, Magali Remaud-Siméon, Pierre Frédéric Emmanuel Monsan
-
Publication number: 20080254166Abstract: Disclosed herein is a food additive containing at least one fiber source selected from the group consisting of digestion-resistant starch, digestion-resistant maltodextrin, digestion-resistant soluble fiber dextrin, digestion-resistant glucose syrup, pullulan, digestion-resistant hemicellulose, digestion-resistant corn syrup, digestion-resistant glucose syrup solids, digestion-resistant corn syrup solids, and digestion-resistant fructose oligomer syrup, wherein each fiber source is present in an amount of at least about 1 gram per 10 g food additive; and at least one probiotic organism selected from the group consisting of Lactobacillus spp., Bifidobacterium spp., Enterococcus spp., Escherichia spp., Streptococcus spp., and Saccharomyces spp., wherein each probiotic organism is present in an amount of at least 100 cells per 10 g food additive. Also disclosed herein is a fortified foodstuff, containing a base foodstuff and a food additive as described above.Type: ApplicationFiled: January 7, 2008Publication date: October 16, 2008Inventor: Susan M. Potter
-
Patent number: 7285297Abstract: The present invention is a composition comprising a plant sterol and a soy protein material and/or and isoflavone selected from genistein, daidzein, glycitein, biochanin A, formononetin, and their naturally occurring glycosides, where the plant sterol comprises at least 0.49% of the composition, by weight. The present invention is also a method for decreasing the blood concentration of total and LDL cholesterol in a human in which a plant sterol and a soy protein material and/or an isoflavone are co-administered to the human, where the plant sterol comprises at least 0.49%, by weight, of the combined weight of the plant sterol and the soy protein material and/or the isoflavone. The present invention is also a method for preventing or minimizing the development of atherosclerosis in a human in which a plant sterol and a soy protein material and/or an isoflavone are co-administered to the human, where the plant sterol comprises at least 0.Type: GrantFiled: June 13, 2003Date of Patent: October 23, 2007Assignee: Archer-Daniels-Midland CompanyInventors: Doyle H. Waggle, Susan M. Potter, Edna C. Henley
-
Publication number: 20040071800Abstract: The present invention is a method for decreasing the blood concentration of total and LDL cholesterol in a human in which a plant sterol and a soy hypocotyl material are co-administered to the human, where the plant sterol comprises at least 0.Type: ApplicationFiled: October 20, 2003Publication date: April 15, 2004Applicant: The Solae Company, LLC.Inventors: Doyle H. Waggle, Susan M. Potter, E. C. Henley
-
Patent number: 6669952Abstract: A composition is provided comprising a plant sterol and a soy protein material and/or and isoflavone selected from genistein, daidzein, glycitein, biochanin A, formononetin, and their naturally occurring glycosides, where the plant sterol comprises at least 0.49% of the composition, by weight. The present invention is also a method for decreasing the blood concentration of total and LDL cholesterol in a human in which the plant sterol and a soy protein material and/or an isoflavone are co-administered to the human, where the plant sterol comprises at least 0.49%, by weight, of the combined weight of the plant sterol and the soy protein material and/or the isoflavone. Also provided is a method for preventing or minimizing the development of atherosclerosis in a human in which a plant sterol and a soy protein material and/or an isoflavone are co-administered to the human, where the plant sterol comprises at least 0.Type: GrantFiled: March 30, 2001Date of Patent: December 30, 2003Assignee: Solae, LLCInventors: Doyle H. Waggle, Susan M. Potter, E. C. Henley
-
Publication number: 20030208791Abstract: This invention relates to an isolated nucleic acid fragment encoding an oxidosqualene cyclase. The invention also relates to the construction of a chimeric gene encoding all or a portion of the isolated polynucleotides of the invention, in sense or antisense orientation, operably linked to a suitable regulatory sequence.Type: ApplicationFiled: September 9, 2002Publication date: November 6, 2003Inventors: Gregory T Bryan, Brian McGonigle, Carl A Maxwell, Susan M Potter, Der-Chyan Hwang
-
Patent number: 6579534Abstract: A composition is provided comprising a plant sterol and a soy protein material and/or and isoflavone selected from genistein, daidzein, glycitein, biochanin A, formononetin, and their naturally occurring glycosides, where the plant sterol comprises at least 0.49% of the composition, by weight. The present invention is also a method for decreasing the blood concentration of total and LDL cholesterol in a human in which the plant sterol and a soy protein material and/or an isoflavone are co-administered to the human, where the plant sterol comprises at least 0.49%, by weight, of the combined weight of the plant sterol and the soy protein material and/or the isoflavone. Also provided is a method for preventing or minimizing the development of atherosclerosis in a human in which a plant sterol and a soy protein material and/or an isoflavone are co-administered to the human, where the plant sterol comprises at least 0.Type: GrantFiled: April 4, 2001Date of Patent: June 17, 2003Assignee: Solae, LLCInventors: Doyle H. Waggle, Susan M. Potter, Edna C. Henley
-
Patent number: 6572876Abstract: A composition is provided comprising a plant sterol and a soy protein material and/or and isoflavone selected from genistein, daidzein, glycitein, biochanin A, formononetin, and their naturally occurring glycosides, where the plant sterol comprises at least 0.49% of the composition, by weight. The present invention is also a method for decreasing the blood concentration of total and LDL cholesterol in a human in which the plant sterol and a soy protein material and/or an isoflavone are co-administered to the human, where the plant sterol comprises at least 0.49%, by weight, of the combined weight of the plant sterol and the soy protein material and/or the isoflavone. Also provided is a method for preventing or minimizing the development of atherosclerosis in a human in which a plant sterol and a soy protein material and/or an isoflavone are co-administered to the human, where the plant sterol comprises at least 0.Type: GrantFiled: March 22, 2001Date of Patent: June 3, 2003Assignee: Solae, LLCInventors: Doyle H. Waggle, Susan M. Potter, E. C. Henley
-
Patent number: 6544566Abstract: A composition is provided comprising a plant sterol and a soy protein material and/or and isoflavone selected from genistein, daidzein, glycitein, biochanin A, formononetin, and their naturally occurring glycosides, where the plant sterol comprises at least 0.49% of the composition, by weight. The present invention is also a method for decreasing the blood concentration of total and LDL cholesterol in a human in which the plant sterol and a soy protein material and/or an isoflavone are co-administered to the human, where the plant sterol comprises at least 0.49%, by weight, of the combined weight of the plant sterol and the soy protein material and/or the isoflavone. Also provided is also a method for preventing or minimizing the development of atherosclerosis in a human in which a plant sterol and a soy protein material and/or an isoflavone are co-administered to the human, where the plant sterol comprises at least 0.Type: GrantFiled: April 23, 1999Date of Patent: April 8, 2003Assignee: Protein Technologies International, Inc.Inventors: Doyle H. Waggle, Susan M. Potter, E. C. Henley
-
Patent number: 6326366Abstract: The present invention relates to a hormone replacement therapy, and a composition useful therein, for women having reduced levels of endogenous estrogen. A mammalian estrogen and an isoflavone which is incapable of being metabolized to equol are co-administered to a woman having a reduced level of endogenous estrogen. The hormone replacement therapy is effective to inhibit or prevent diseases or conditions resulting from, or exacerbated by, a reduction in endogenous estrogen including: coronary heart disease, cardiovascular disease, osteoporosis, loss of cognitive function, urinary incontinence, weight gain, fat mass gain, and vasomotor symptoms. A composition for use in the hormone replacement therapy of the present invention contains a mammalian estrogen and at least one isoflavone, where the isoflavone is incapable of being metabolized to equol by a human, and where the composition contains less than 10% by weight of isoflavones and phytoestrogens capable of being metabolized to equol by a human.Type: GrantFiled: August 22, 2000Date of Patent: December 4, 2001Assignee: Protein Technologies InternationalInventors: Susan M. Potter, Edna C. Henley, Richard B. Taylor
-
Publication number: 20010029248Abstract: The present invention is a composition comprising a plant sterol and a soy protein material and/or and isoflavone selected from genistein, daidzein, glycitein, biochanin A, formononetin, and their naturally occurring glycosides, where the plant sterol comprises at least 0.49% of the composition, by weight. The present invention is also a method for decreasing the blood concentration of total and LDL cholesterol in a human in which a plant sterol and a soy protein material and/or an isoflavone are co-administered to the human, where the plant sterol comprises at least 0.49%, by weight, of the combined weight of the plant sterol and the soy protein material and/or the isoflavone. The present invention is also a method for preventing or minimizing the development of atherosclerosis in a human in which a plant sterol and a soy protein material and/or an isoflavone are co-administered to the human, where the plant sterol comprises at least 0.Type: ApplicationFiled: March 30, 2001Publication date: October 11, 2001Applicant: Protein Technologies International, Inc.Inventors: Doyle H. Waggle, Susan M. Potter, E. C. Henley
-
Publication number: 20010026814Abstract: The present invention is a composition comprising a plant sterol and a soy protein material and/or and isoflavone selected from genistein, daidzein, glycitein, biochanin A, formononetin, and their naturally occurring glycosides, where the plant sterol comprises at least 0.49% of the composition, by weight. The present invention is also a method for decreasing the blood concentration of total and LDL cholesterol in a human in which a plant sterol and a soy protein material and/or an isoflavone are co-administered to the human, where the plant sterol comprises at least 0.49%, by weight, of the combined weight of the plant sterol and the soy protein material and/or the isoflavone. The present invention is also a method for preventing or minimizing the development of atherosclerosis in a human in which a plant sterol and a soy protein material and/or an isoflavone are co-administered to the human, where the plant sterol comprises at least 0.Type: ApplicationFiled: March 22, 2001Publication date: October 4, 2001Applicant: Protein Technologies International, Inc.Inventors: Doyle H. Waggle, Susan M. Potter, Edna C. Henley
-
Publication number: 20010024666Abstract: The present invention is a composition comprising a plant sterol and a soy protein material and/or and isoflavone selected from genistein, daidzein, glycitein, biochanin A, formononetin, and their naturally occurring glycosides, where the plant sterol comprises at least 0.49% of the composition, by weight. The present invention is also a method for decreasing the blood concentration of total and LDL cholesterol in a human in which a plant sterol and a soy protein material and/or an isoflavone are co-administered to the human, where the plant sterol comprises at least 0.49%, by weight, of the combined weight of the plant sterol and the soy protein material and/or the isoflavone. The present invention is also a method for preventing or minimizing the development of atherosclerosis in a human in which a plant sterol and a soy protein material and/or an isoflavone are co-administered to the human, where the plant sterol comprises at least 0.Type: ApplicationFiled: April 4, 2001Publication date: September 27, 2001Applicant: Protein Technologies International, Inc.Inventors: Doyle H. Waggle, Susan M. Potter, Edna C. Henley
-
Patent number: 5855892Abstract: A method of altering the concentration of cholesterol constituents in human blood is provided. A daidzein material is administered to a human to increase the concentration of HDL-cholesterol and to decrease the level of LDL-cholesterol in the blood. The daidzein material may be administered in a pharmaceutical composition, or in a dietary supplement, including soy protein based dietary supplements. Utilization of daidzein to increase the concentration of HDL cholesterol and to decrease the concentration of LDL-cholesterol in the blood reduces the risk of atherosclerosis and vascular disease by providing more health beneficial HDL-cholesterol and reducing the level of atherosclerosis-inducing LDL-cholesterol.Type: GrantFiled: September 19, 1997Date of Patent: January 5, 1999Inventors: Susan M. Potter, Edna C. Henley, Doyle H. Waggle